Our innovative mindset and human resources, is the key to our succes..
PEG & Reponex Management Team
Our team is made up of visionary thinkers and experts, dedicated to positioning Pharma Equity Group and Reponex for long-term success

Christian Tange
Chief Executive Officer
MORE
Senior executive with 25 years of
experience developing international growth companies in Europe and USA. Holding
executive management and board positions in public listed (NASDAQ) and private
equity owned companies.
Particularly experienced in executing on financial performance strategies for
companies with ambitious growth or exit plans. Further experienced in
developing product and price strategies as well as structuring organizations
and implementing cross organizational processes. Positive results from
improving profitability and efficiency.
Strong negotiator with positive result from public offerings (IPOs) and private
fundraising using various equity and debt instruments from European, American
and Chinese investors. Experienced in performing international M&A
transactions and handling Investor Relations.
Highly motivated by transforming complexity into simple and efficient business
solutions

Sebastian Bo Jakobsen
CEO – Reponex Pharmaceuticals
MORE
Research, Data science and line management.
Sebastian has a Master’s degree in Cognitive Science, Cand IT, from Aarhus University. He entered the pharmaceutical industry in 2020. His professional journey has seen him take on diverse roles, from data scientist, scientific developer to CEO. Currently serving as the Manager of Scientific Development, Sebastian plays a pivotal role in leading teams and offering crucial support to Reponex’s drug development projects across CMC, non-clinical, and clinical areas.
He actively supports the management of Reponex with his great overview and hereby support the development of strategic decisions that guide the company’s future endeavors.

Lars Otto Uttenthal
Chief Medical Officer – Reponex Pharmaceuticals
MORE
Lars Otto Uttenthal (Dr. Phil. Oxford) brings a wealth of expertise to the table with a distinguished career spanning over 45 years in clinical medicine and biomedical research.
With a strong academic background, he has previously conducted research at renowned institutions such as the Universities of Oxford, London and Madrid, and held the position of Professor of Biochemistry at the University of Salamanca.
In addition to his impressive research background, Dr. Uttenthal has over 22 years of experience in leading research and development efforts within the medical industry.
Notably, he excels in the domain of intellectual property, having successfully conceived a considerable number of patent applications and navigated them through the application process, making him a valuable asset in the world of innovative healthcare.
PEG & Reponex Employees

Sebastian Bo Jakobsen
CEO – Reponex Pharmaceuticals
MORE
Research, Data science and line management.
Sebastian has a Master’s degree in Cognitive Science, Cand IT, from Aarhus University. He entered the pharmaceutical industry in 2020. His professional journey has seen him take on diverse roles, from data scientist, scientific developer to CEO. Currently serving as the Manager of Scientific Development, Sebastian plays a pivotal role in leading teams and offering crucial support to Reponex’s drug development projects across CMC, non-clinical, and clinical areas.
He actively supports the management of Reponex with his great overview and hereby support the development of strategic decisions that guide the company’s future endeavors.

Ved Parkash
CMC Scientist – Drug Development
MORE
Professional Summary:
· Over eight years of experience in product development
and research.
· Specializes in the development and characterization of
solid dosage forms, including tablets and capsules.
· Expertise in pre-formulation and drug product
development using various solubility enhancing techniques.
· Experienced in process development and validation for
mixing, granulation, and tableting processes.
· Aims to expand involvement in broader project scopes
and innovations within the pharmaceutical industry.
Work Experience:
· Business Developer, SPER Market Research, India (EU
Division).
· Expanded European client base through targeted
business development strategies.
· Associate Scientist, Global Research Novo Nordisk A/S,
Copenhagen.
· Developed new oral insulin formulations for
pre-clinical and clinical studies.
· Research Scientist, Jubilant Life Sciences Ltd, India,
· Focused on the development and characterization of formulations
for clinical studies.
Education:
· PhD in Pharmaceutical Sciences, OPJS University,
India, 2014-2019
· Thesis on the development and optimization of dermal
drug delivery systems.
· Master in Pharmacy, Rajiv Academy for Pharmacy,
Mathura, India, 2007-2009
· Thesis focused on orally disintegrating tablets for the geriatric population.

Rikke Sejer
Qualified Person (QP)
MORE
With over 30 years of experience in GMP and Quality within the pharmaceutical industry, she brings deep expertise in GMP project execution and maintenance, Quality Management Systems, and regulatory compliance across EU and FDA frameworks.
Currently employed at Pharma Relations, she is highly driven by process optimization and enabling teams to focus on value-creating work. Her approach is rooted in a strong quality mindset, and she thrives in project management roles where she can combine structure, compliance, and continuous improvement across cross-functional teams.

René Egebro
Principal CMC consultant
MORE
Chemistry manufacturing and controls.
Rene Egebro, a Cand. Pharm. graduate from the University of Copenhagen, has accumulated over 20 years of experience in pharmaceutical and biopharmaceutical development.
His extensive expertise covers CMC, analytical development, outsourcing, manufacturing, quality control, and more, encompassing various product types.
As a former CMC outsourcing manager, he successfully guided numerous projects from discovery to launch, compiling over 20 IMPD’s/IND’s.
Before founding his consultancy in 2012, Rene worked at prominent companies like Novo Nordisk, Neurosearch, and H. Lundbeck. He specializes in aiding small biotech and pharma companies, employing a proactive, detail-oriented, and energetic approach. Rene excels as a team player and communication expert, with skills extending to optimizing CMC costs for sponsors.

Peter Ekman
Financial Manager
MORE
PE serves as Financial Manager in Pharma Equity Group and in Reponex Pharmaceuticals.
PE has more than 20 years of experience as CFO/CA and board member of various companies. He has extensive experience within all aspects of economy and accounting, including financial management, financial accounting (IFRS & ÅRL) ect.
PE has in several years worked for a listed company including a period as board member. He has experience with rules for listed companies and listed companies’ capital ratios.
PE has previously been CEO of his own company and board member for several different companies and thus has extensive experience with most aspects of companies’ administrative and financial matters.

Margrethe Erbou Andersen
Regulatory Affairs Consultant
MORE
With 25 years of experience in the pharmaceutical industry, Margrethe is a regulatory affairs professional with a strong scientific foundation and extensive knowledge across the entire product life cycle—from early clinical development to post-approval management. She has a particular focus on pre-approval activities for small to mid-sized pharmaceutical companies and has worked closely with regulatory agencies in Europe, the US, and Japan. Her background also includes experience with generics and nine years of specialized work in CMC.
Margrethe combines strategic insight with hands-on execution, supported by solid project management and leadership capabilities. In addition to her industry work, she contributes as a lecturer at Atrium, a leading life science education provider affiliated with the University of Copenhagen.

Lars Skriver
Principal CMC Consultant
MORE
Biochemistry, Protein Research and Industry background.
Lars Skriver is a highly experienced professional with a strong background in biochemistry, boasting over 40 years of expertise in lipid and protein chemistry.
With over three decades of dedicated service in the pharmaceutical industry, he has held key leadership roles, including serving as the Co-founder and Managing Director at L&K Bioscience and as the COO at Serendex Pharmaceuticals A/S.
Prior to that, Lars contributed his knowledge as a Senior Science Officer at Savara Pharmaceuticals and gained valuable experience through various pharmaceutical development positions at Novo Nordisk A/S. His wealth of experience encompasses extensive expertise in Chemistry, Manufacturing, and Controls (CMC), making him a valuable asset to the field